Mark A. Kronenfeld is Director at Pacira Pharmaceuticals, Inc. (PCRX). They have made 5 open-market trades across 1 company since 2013, most recently 2025-06-11.
CIK 0001578074
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
5 open-market purchases totalling $266K since 2013, never a sale. Across 5 scored buys the stock is up 1.2% at ninety days, and 0.8 points ahead of the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| PCRX | 31,065 | $1.1M |
Shares reported on the most recent Form 4, priced at the 2026-03-19 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 60% | 100% | 80% |
| Avg Move | -4.0% | +4.2% | +1.2% |
| Alpha | -2.3% | +2.2% | +0.8% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| PCRX | SELL · 10b5-1 | 2023-06-08 | 2023-06-12 | $37.04 | $556K | +10.8% | +1.1% | -7.6% |
| PCRX | BUY | 2019-03-06 | 2019-03-08 | $38.97 | $66K | +7.1% | +7.6% | +14.1% |
| PCRX | BUY | 2018-08-28 | 2018-08-30 | $44.61 | $45K | +0.8% | +3.5% | +4.3% |
| PCRX | BUY | 2017-11-10 | 2017-11-13 | $41.60 | $42K | +8.4% | +8.0% | -14.3% |
| PCRX | SELL · 10b5-1 | 2016-06-06 | 2016-06-08 | $46.95 | $42K | -17.7% | -21.9% | -12.5% |
| PCRX | BUY | 2014-11-03 | 2014-11-04 | $90.48 | $77K | -18.1% | +0.8% | +0.8% |
| PCRX | BUY | 2013-09-11 | 2013-09-13 | $37.01 | $37K | -18.1% | +0.8% | +0.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.